Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dextroamphetamine Study Including Healthy Children Will Be First Test For Pediatric Ethics Subcommittee

This article was originally published in The Pink Sheet Daily

Executive Summary

NIH study proposes single-dose administration to both children with attention deficit/hyperactivity disorder and healthy volunteers. Institutional Review Board requested special review from HHS after two divided votes.

You may also be interested in...



Attention Deficit Study In Healthy Children Can Proceed Under Certain Conditions, Cmte. Says

NIH proposal to administer dextroamphetamine to healthy children represents only a slightly greater than minimal risk to study participants, FDA's Pediatric Ethics Subcommittee says. The Pediatric Advisory Committee will review the recommendations Sept. 15.

Attention Deficit Study In Healthy Children Can Proceed Under Certain Conditions, Cmte. Says

NIH proposal to administer dextroamphetamine to healthy children represents only a slightly greater than minimal risk to study participants, FDA's Pediatric Ethics Subcommittee says. The Pediatric Advisory Committee will review the recommendations Sept. 15.

FDA Analysis Of Antidepressant Pediatric Suicidality Data To Be Reviewed Sept. 13-14

Joint meeting of Psychopharmacologic and newly formed Pediatric Advisory Committees will review analysis performed by expert group assembled by Columbia University. Future research needs in pediatric suicidality will also be addressed.

Topics

UsernamePublicRestriction

Register

PS060340

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel